哌嗪1-(2,2-2-二氟乙基)-盐酸盐(1:2) | 1225276-98-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 哌嗪1-(2,2-2-二氟乙基)-盐酸盐(1:2)
• 英文名称: 1-(2,2-Difluoroethyl)piperazine dihydrochloride
• 英文别名: 1-(2,2-difluoroethyl)piperazine;dihydrochloride
• CAS: 1225276-98-1
• 化学式: C6H14Cl2F2N2
• 分子量: 223.09
• InChiKey: GSQXYVLILCFUHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.0
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

文献信息

• HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS
  申请人：Härter Michael

  公开号：US20130196964A1

  公开（公告）日：2013-08-01

  The present application relates to novel aryl compounds with heterocyclic substituents, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及具有杂环取代基的新型芳基化合物，其制备方法，它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应缺氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步治疗措施结合使用。
• SUBSTITUTED PYRIDOBENZODIAZEPINONE-DERIVATIVES AND USE THEREOF
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20170253602A1

  公开（公告）日：2017-09-07

  The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及新型(3-羟基苯基)氨基取代的吡啶并[2,3-b][1,5]苯二氮杂二环己酮衍生物，以及其制备方法，单独或联合用于治疗和/或预防疾病的用途，以及用于生产用于治疗和/或预防疾病的药物的用途，特别是对血管生成障碍和细胞过度增殖障碍的治疗，其中新生血管化起作用，例如眼科疾病和癌症和肿瘤。这种治疗可以作为单独治疗或与其他药物或进一步治疗措施结合使用。
• Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
  申请人：Genentech, Inc.

  公开号：US10988478B1

  公开（公告）日：2021-04-27

  Compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

  本文描述了式 0、式 I 和式 II 的化合物以及用作白细胞介素-1 受体相关激酶（IRAK4）抑制剂的方法。
• HETEROCYCLISCH SUBSTITUIERTE ARYL-VERBINDUNGEN ALS HIF-INHIBITOREN
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP2356113A1

  公开（公告）日：2011-08-17
• SUBSTITUIERTE PYRIDOBENZODIAZEPINON-DERIVATE UND IHRE VERWENDUNG
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP3223821A1

  公开（公告）日：2017-10-04